LongBio Pharma-B(01779.HK): Public Subscription Opens Today, Entry Fee Approx. HK$4,851; Cornerstone Investors Pledge About US$8.7 Million

NewTimeSpace News: LongBio Pharma (Suzhou) Co., Ltd. (01779.HK) commences its public subscription on May 28, 2026, and is expected to be listed on June 5, 2026.
According to the prospectus, the company proposes a global offering of 14,193,150 H-shares (subject to the exercise of the over-allotment option), including 1,419,350 H-shares for Hong Kong public offering (subject to reallocation). The offer price is fixed at HK$96.06 per share. Each board lot is 50 shares, with an entry fee of approximately HK$4,851.44.
Calculated at the offer price of HK$96.06 per share, cornerstone investors will take up a total of 7,090,400 offered shares with a total subscription value of around US$8.7 million. Their shareholding represents 49.96% of the total offering (assuming no exercise of the over-allotment option) and about 9.56% of the total issued share capital.
The Hong Kong public offering will close at 12:00 noon on June 2, 2026, and the allotment results will be announced on June 4, 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.